EUCTR2013-001058-85-DE进行中（未招募）1 期
EFFECTS OF BENFOTIAMINE ON INTRAEPIDERMAL NERVE FIBER DENSITY (IENFD) AND DIABETIC NEUROPATHY IN SUBJECTS WITH SENSORIMOTOR DIABETIC POLYNEUROPATHY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP PILOT STUDY OVER 12 MONTHS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed and dated written informed consent obtained before any study-related activities
- •2.Have type 1 or type 2 diabetes mellitus based on the disease diagnostic criteria (WHO) classification on ongoing insulin or/and oral antidiabetic therapy with a stable regimen for the previous 3 months
- •3.Male or female subjects aged between 18 and 75 years, inclusive
- •4.Have an HbA1c level = 9.5% without optimizing potential
- •5.(mTCNS = (above or equal to) 6) OR (a score on the MNSI questionnaire of =4 or a score on the MNSI examination =2.5)
- •6.Medical history without major pathology (with the exception of type 2 diabetes) as judged by the investigator, especially no major peripheral artery disease.
- •7.Body mass index (BMI) between 25 and 45kg/m2, both inclusive
- •8.Ability and willingness to abstain from alcohol and from engaging in strenuous physical activity from 24 hours prior to each visit until discharge from the unit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 11
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •1.Subjects with secondary forms of diabetes such as due to pancreatitis.
- •2.Current or previous treatment (less than 6 months) with benfotiamine, B-vitamins, vitamin B complex, alpha lipoic acid or actovegin.
- •3.Have any contraindications, known allergy, or hypersensitivity to benfotiamine.
- •4.Have any contraindications, known allergy, or hypersensitivity to local anesthetics.
- •5.Neuropathy by other origin than diabetes.
- •6.Other severe pain that might impair the assessment of neuropathic pain.
- •7.Treatment with more than one of following: tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, anticonvulsants, class I antiarrhythmics with Na-channel inhibition (mexiletine, flecainid, propafenon and others) or neuroleptics in patients receiving these drugs for neuropathic pain.
- •8.Have participated in an interventional medical, surgical, or pharmaceutical study within the last three months prior to entry into the study.
- •9.Women of child-bearing age who are pregnant, lactating or plan a pregnancy within the next 24 months.
- •10.Patients on systemic glucocorticoid treatment (except topic or inhalative preparations) within the last 3 months prior to screening.
- •11.Subjects with any severe medical or surgical history of conditions likely to confound study assessments or study endpoints, for example but not limited to haemoglobinopathies, inflammatory bowel disease, cystic fibrosis, bariatric surgery and/or any surgery shortening the intestine, history of galactose intolerance, lactose- or glucose-galactose-malabsorption.
- •12.Subjects with a suspicion for malignant diseases or a history of a malignant disease within the last 10 years.
- •13.As judged by the investigator, serious and/or unstable coronary heart disease (unstable angina, myocardial infarction within the preceding 6 months), congestive heart failure of New York Heart Association Class III or worse, uncontrolled hypertension, history of congenital QT-syndrome within family, history of stroke (within the preceding 6 months) or serious peripheral vascular disease.
- •14.Clinically significant vital signs including known bradycardia with pulse rate < 50/min.
- •15.Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis or coagulation screening tests, as judged by the Investigator.
- •16.Clinical or laboratory evidence of hepatic dysfunction or disease; laboratory evidence defined as any of the following parameters: alkaline phosphatase, ALT, AST or bilirubin > 3x ULN. Isolated mild rise in bilirubin considered to be due to Gilbert’s condition is allowed.
- •17.Chronic pancreatitis.
- •18.Uncontrolled high blood pressure (DBP > 95 mmHg and/or SBP > 160 mmHg), unless clearly documented to be white-coat hypertension
- •19.History of any psychiatric condition that might impair the subject’s ability to understand or to comply with the requirements of the study or to provide informed consent.
- •20.Currently active or history of alcohol abuse (defined as an intake of more than 24 units of alcohol per week; one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits) or drug addiction (including soft drugs like cannabis products).
- •21.Use of concomitant medication which would be likely to interact with benfotiamine (according to the subject information leaflet).
- •22.Subjects known to be positive for Hepatitis B surface antigen or Hepatitis C antibodies (or diagnosed with active hepatitis according to local
研究者
相似试验
Unknown
3 期
Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)Diabetic NeuropathiesNCT01868191Diabetes Schwerpunktpraxis22
招募中
不适用
Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome PatientsComplex Regional Pain SyndromesNCT03977012Seoul National University Hospital20
进行中（未招募）
不适用
Effect of the location where you stick the fentanyl patch on its drug levels.EUCTR2012-000999-41-NL14
招募中
不适用
comparison of pain killer patch with pain relief procedure for inguinal surgeriesCTRI/2022/11/047271All India Institute of Medical Sciences, Bibinagar
进行中（未招募）
1 期
Muscular changes after injection of Botulinumtoxin illustrated by Magnetic Resonance Tomography over a period of 16 weeks and the impact of muscle before injectioSpastic hemiparesis with involvement of the M. biceps brachiiEUCTR2017-003117-25-ATMedical University of Vienna28